No clear genotoxic potential; negative Ames and in vitro chromosome aberration assays
“Clascoterone did not display clear genotoxic potential in a standard battery of genetic toxicity studies. Clascoterone was not mutagenic in an in vitro reverse bacterial mutation assay or clastogenic in an in vitro chromosome aberration assay.”
✓ VerifiedFDA multi-discipline review, p. 35Source ↗
Carcinogenicity
2-year topical rat study (0.1-5% cream): not carcinogenic
“Clascoterone cream (0.1%, 1%, or 5%) was not carcinogenic after daily topical administration in a 2-year carcinogenicity study in rats.”
✓ VerifiedFDA multi-discipline review, p. 149Source ↗
Reproductive & developmental
Rat EFD: malformations at all doses; no developmental NOAEL
“a developmental NOAEL could not be determined because clascoterone-related malformations were noted in three fetuses at the low dose (LD) and 1 fetus each at the mid dose (MD) and HD.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Safety pharmacology
Low-potency hERG inhibition (40% at 10 uM)
“In a pilot hERG assay, clascoterone produced low potency dose-related inhibition of the hERG potassium current (up to 40% inhibition at the highest concentration evaluated [10μM])”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative